Optimizing Lipid-Lowering Strategies Beyond Current Evidence.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Drugs and Therapy Pub Date : 2025-09-12 DOI:10.1007/s10557-025-07778-y

Mucahit Yetim, Abdülmelik Birgün, Macit Kalçık

引用次数: 0

Abstract

This letter addresses the recent study by Sohn et al., which compared moderate-intensity atorvastatin plus ezetimibe with high-intensity atorvastatin in patients with angina undergoing PCI. We emphasize key limitations, including the absence of LDL-C values, potential residual confounding, and the small CKD subgroup sample size. Furthermore, adherence and safety outcomes were not adequately assessed. While the study supports non-inferiority of combination therapy, further prospective research is needed to clarify optimal lipid-lowering strategies in this high-risk population.

查看原文本刊更多论文

优化降脂策略超越现有证据。

这封信提到了Sohn等人最近的一项研究，该研究比较了中等强度阿托伐他汀加依折替贝与高强度阿托伐他汀在接受PCI的心绞痛患者中的作用。我们强调关键的局限性，包括缺乏LDL-C值，潜在的残留混淆，以及较小的CKD亚组样本量。此外，依从性和安全性结果没有得到充分评估。虽然该研究支持联合治疗的非劣效性，但需要进一步的前瞻性研究来阐明这一高危人群的最佳降脂策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Drugs and Therapy 医学-心血管系统

CiteScore

8.30

自引率

0.00%

发文量

110

审稿时长

4.5 months

期刊介绍： Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field. Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients. Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.